Shots:
- The EC has approved Lenivia (Q3W) for the reduction of pain associated with osteoarthritis in dogs
- Lenivia showed increased mobility & decreased pain after a single administration in a 9mos. field study, along with favorable safety in dogs
- Lenivia, a monoclonal antibody targeting NGF, is designed to provide longer-lasting pain relief in osteoarthritis by binding to a distinct NGF site
Ref: Zoetis | Image: Zoetis | Press Release
Related News: Zoetis’ Lenivia (Izenivetmab) Receives the CVMP’s Recommendation for Osteoarthritis Pain Relief in Dogs
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information connect with us at connect@pharmashots.com
